The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases

Abstract This study aimed to prove that the FibroScan-aspartate aminotransferase (FAST) scores can be used to stratify disease severity in a Japanese cohort with fatty liver diseases [metabolic dysfunction-associated fatty liver disease (MAFLD) and nonalcoholic fatty liver disease (NAFLD)]. All the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hideki Fujii, Shinya Fukumoto, Masaru Enomoto, Sawako Uchida-Kobayashi, Tatsuo Kimura, Akihiro Tamori, Yuji Nadatani, Shingo Takashima, Naoki Nishimoto, Norifumi Kawada
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e1ed949c073c40da8db5b7808859e73e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e1ed949c073c40da8db5b7808859e73e
record_format	dspace
spelling	oai:doaj.org-article:e1ed949c073c40da8db5b7808859e73e2021-12-02T16:14:46ZThe FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases10.1038/s41598-021-93435-x2045-2322https://doaj.org/article/e1ed949c073c40da8db5b7808859e73e2021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93435-xhttps://doaj.org/toc/2045-2322Abstract This study aimed to prove that the FibroScan-aspartate aminotransferase (FAST) scores can be used to stratify disease severity in a Japanese cohort with fatty liver diseases [metabolic dysfunction-associated fatty liver disease (MAFLD) and nonalcoholic fatty liver disease (NAFLD)]. All the participants (n = 2254) underwent liver stiffness measurements and controlled attenuation parameter assessments. We compared the clinical characteristics of the patients with MAFLD and NAFLD using the FAST scores and explored the independent determinants of FAST scores ≥ 0.35, which indicated possible progressive disease. Overall, MAFLD was diagnosed in 789 patients (35.0%), while NAFLD was diagnosed in 618 (27.4%). The proportion of patients that had a condition that suggested progressive liver disease was higher in those with MAFLD than in those with NAFLD [68 (8.6%) vs 48 (7.7%)]. The area under the receiver-operating characteristic curve of the FAST score for diagnosing advanced fibrosis was 0.969 in MAFLD and 0.965 in NAFLD. Multivariate analyses determined that diabetes mellitus, alanine aminotransferase (ALT) levels, fatty liver index, and Fibrosis-4 index independently predict FAST scores ≥ 0.35 in patients with MAFLD. ALT levels had the strongest correlation with the FAST scores (p = 0.7817). The FAST score could stratify the disease severity in the Japanese cohort with fatty liver diseases.Hideki FujiiShinya FukumotoMasaru EnomotoSawako Uchida-KobayashiTatsuo KimuraAkihiro TamoriYuji NadataniShingo TakashimaNaoki NishimotoNorifumi KawadaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hideki Fujii Shinya Fukumoto Masaru Enomoto Sawako Uchida-Kobayashi Tatsuo Kimura Akihiro Tamori Yuji Nadatani Shingo Takashima Naoki Nishimoto Norifumi Kawada The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases
description	Abstract This study aimed to prove that the FibroScan-aspartate aminotransferase (FAST) scores can be used to stratify disease severity in a Japanese cohort with fatty liver diseases [metabolic dysfunction-associated fatty liver disease (MAFLD) and nonalcoholic fatty liver disease (NAFLD)]. All the participants (n = 2254) underwent liver stiffness measurements and controlled attenuation parameter assessments. We compared the clinical characteristics of the patients with MAFLD and NAFLD using the FAST scores and explored the independent determinants of FAST scores ≥ 0.35, which indicated possible progressive disease. Overall, MAFLD was diagnosed in 789 patients (35.0%), while NAFLD was diagnosed in 618 (27.4%). The proportion of patients that had a condition that suggested progressive liver disease was higher in those with MAFLD than in those with NAFLD [68 (8.6%) vs 48 (7.7%)]. The area under the receiver-operating characteristic curve of the FAST score for diagnosing advanced fibrosis was 0.969 in MAFLD and 0.965 in NAFLD. Multivariate analyses determined that diabetes mellitus, alanine aminotransferase (ALT) levels, fatty liver index, and Fibrosis-4 index independently predict FAST scores ≥ 0.35 in patients with MAFLD. ALT levels had the strongest correlation with the FAST scores (p = 0.7817). The FAST score could stratify the disease severity in the Japanese cohort with fatty liver diseases.
format	article
author	Hideki Fujii Shinya Fukumoto Masaru Enomoto Sawako Uchida-Kobayashi Tatsuo Kimura Akihiro Tamori Yuji Nadatani Shingo Takashima Naoki Nishimoto Norifumi Kawada
author_facet	Hideki Fujii Shinya Fukumoto Masaru Enomoto Sawako Uchida-Kobayashi Tatsuo Kimura Akihiro Tamori Yuji Nadatani Shingo Takashima Naoki Nishimoto Norifumi Kawada
author_sort	Hideki Fujii
title	The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases
title_short	The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases
title_full	The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases
title_fullStr	The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases
title_full_unstemmed	The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases
title_sort	fibroscan-aspartate aminotransferase score can stratify the disease severity in a japanese cohort with fatty liver diseases
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/e1ed949c073c40da8db5b7808859e73e
work_keys_str_mv	AT hidekifujii thefibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases AT shinyafukumoto thefibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases AT masaruenomoto thefibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases AT sawakouchidakobayashi thefibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases AT tatsuokimura thefibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases AT akihirotamori thefibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases AT yujinadatani thefibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases AT shingotakashima thefibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases AT naokinishimoto thefibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases AT norifumikawada thefibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases AT hidekifujii fibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases AT shinyafukumoto fibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases AT masaruenomoto fibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases AT sawakouchidakobayashi fibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases AT tatsuokimura fibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases AT akihirotamori fibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases AT yujinadatani fibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases AT shingotakashima fibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases AT naokinishimoto fibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases AT norifumikawada fibroscanaspartateaminotransferasescorecanstratifythediseaseseverityinajapanesecohortwithfattyliverdiseases
_version_	1718384323189538816

The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases

Ejemplares similares